Clinical Research in the Laboratory Medicine Department

The laboratory department is an essential component of our healthcare institution, dedicated to conducting research that enhances our understanding of various medical conditions and improves patient care. Our team of researchers, scientists, and technicians works closely with national and international partners to ensure a collaborative and comprehensive approach to biomedical research.

Our research covers a broad range of fields, including molecular biology, microbiology, and hematology. Utilizing established methodologies, we strive to enhance our understanding of certain conditions and contribute to the development of effective therapeutic strategies. The department’s commitment to quality research is demonstrated through our publications in reputable scientific journals and participation in professional conferences.

We prioritize the integration of research findings into clinical practice, aiming to directly benefit patient care. By maintaining high standards of scientific inquiry and fostering a culture of continuous improvement, the laboratory department supports the overall mission of our institution to provide excellent healthcare services.

Areas of Current Active Research

1. Impact of conflict/war disasters on blood banks and transfusion services in the Eastern Mediterranean Region
2. Paths to improve voluntary blood donations in public/private blood donation systems such as Lebanon
3. Assessment of Vitamin B12 Deficiency Prevalence and Associated Factors
4. Obstructive Pyelonephritis Caused by Kocuria kristinae: A Unique Case Report
5. Epidemiology of Resistance Pattern in UTI in Lebanon

Projects in Development

1. Blood supply in conflict zones-Role of hospital Blood banks and NGOs in assisting with the blood supply in conflict zones-Ukraine, Lebanon
2. Phase 3 double blind, randomized study to compare the efficacy and safety of ACE-536 versus placebo in subjects with myeloproliferative neoplasms-associated myelofibrosis on concomitant KAK-2 inhibitor therapy and who require red blood cell transfusions.
3. Phase III, randomized, open-label study evaluating the efficacy and safety of Giredestrant in combination with Phesgo versus Phesgo after induction therapy with Phesgo +Taxanein patients with previously untreated HER-2 positive, estrogen receptor positive locally-advanced or metastatic breast cancer

Research Partners and Collaborators

Extended Research Team

• Hind Rahban, MD- Laboratory Medicine Department, Full Timer
• Rita Feghali , MD- Laboratory Medicine Department, Full Timer
• Tarek Bou Assi, MD- Laboratory Medicine Department, Part-timer
• Roula Husni, MD, Professor - Internal Medicine Department
• Nada Ayoub, MD- Internal Medicine Department

External Research Team 

Lebanon

• Ziad El Rassi, MD Professor, General Surgery Department, SGHUMC
• Antoine Haddad, MD, Laboratory Medicine Department, Sacre Coeur Hospital

     Abroad

• May Raouf, MD, Dubai Blood Donation Center, Dubai-UAE
• Quentin Eichbaum, MD, PhD, Vanderbilt University School of Medicine, Nashville, Tennessee- USA
• Arwa El Riyami, MD, Sultan Qaboos University Hospital and University Medical City, Oman